Vascular endothelial growth factor (VEGF) inhibitor, Eydenzelt (aflibercept-boav), is now approved to treat retinal disease ...

Eydenzelt is a vascular endothelial growth factor inhibitor referencing Eylea, which is jointly developed by Regeneron ...

REGENXBIO completed enrollment in its ATMOSPHERE and ASCENT trials that will be evaluating surabgene lomparvovec (sura-vec, ...

The Food and Drug Administration (FDA) has approved Eydenzelt ® (aflibercept-boav), a biosimilar to Eylea ® (aflibercept).

Nail clubbing, characterized by rounded, thickened, and downward-curved nails, serves as a subtle yet significant indicator ...

Light responsive nanomotors dissolve blood clots and repair vessel tissue by combining catalytic activity, targeted motion, and gentle heating for coordinated thrombolysis and endothelial regeneration ...

Aeston West is thrilled to launch in the beauty market to provide a clinically grounded and botanically informed product ...

D Molecular Therapeutics (FDMT) offers attractive growth potential with strong cash reserves and promising late-stage gene ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; ...

An mRNA vaccine developed by researchers from Japan suppressed abnormal blood vessel growth or neovascularization in the ...

Twenty-eight blood-based protein biomarkers, including substance P and CRP, are elevated during sickle cell vaso-occlusive episodes, but not chronic pain.

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab ...